Inogen SEC filings document a respiratory medical technology business that develops, manufactures, markets, sells, and rents respiratory products for homecare use. Results filings and annual proxy materials cover operating performance, executive compensation, director elections, board committees, equity plans, and stockholder voting matters.
Recent Form 8-K disclosures also record share repurchase authorization, leadership and compensatory arrangements, material governance agreements, and Regulation FD communications. The filing record ties these corporate actions to Inogen’s common stock, board oversight, and product portfolio in portable oxygen, airway clearance, stationary oxygen, and CPAP categories.
Kevin Raymond Smith, CEO, President and a director of Inogen Inc (INGN), reported acquiring 1,500 shares of Common Stock on 09/01/2025 at a purchase price of $7.99 per share under the company’s 2014 Employee Stock Purchase Plan. After the purchase, Mr. Smith beneficially owns 71,774 shares directly. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/03/2025. The filing indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c)'s affirmative defense.
Inogen, Inc. reported consolidated second-quarter revenue of $92.3 million, up 4.0% year-over-year, driven by higher sales revenue of $79.2 million as unit shipments rose to ~49,000 systems versus ~41,300 a year earlier. Rental revenue declined 8.6% to $13.1 million, reflecting a shift toward lower private-payor reimbursement.
Gross margin narrowed to 44.8% from 48.1%, attributed to customer/channel mix and higher materials costs including semiconductor premiums. The company reported a net loss of $4.152 million in Q2 and a six-month loss of $10.326 million, while operating activities used $12.44 million of cash year-to-date. Liquidity remained solid with cash and cash equivalents of $103.7 million and total cash, cash equivalents and restricted cash of $104.96 million.
Corporate developments included a $27.21 million private placement with Yuwell, a Strategic Collaboration Agreement with Yuwell to broaden product distribution and accelerate Chinese market entry, and completion of earnout payments related to the Physio-Assist acquisition. Management is evaluating recent U.S. tax legislation and continues to record a valuation allowance on deferred tax assets.